Trial Profile

A global clinical trial for mesenchymal stromal cells NR-20201

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 05 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mesenchymal stem cell therapy (Primary)
Indications Stroke
Focus Adverse reactions

Most Recent Events

05 Apr 2025 New trial record
18 Mar 2025 According to a Tasly Pharmaceutical Group media release, China's Center for Drug Evaluation (CDE) approved Tasly's IND application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com